A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI 808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs PTI 808 (Primary) ; PTI 428; PTI-801 Proteostasis Therapeutics
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Proteostasis Therapeutics
- 02 Jul 2018 Status changed from active, no longer recruiting to recruiting.
- 18 May 2018 Planned number of patients changed from 66 to 135.
- 18 May 2018 Planned End Date changed from 30 Jun 2019 to 1 Jun 2019.